The current standard neo-adjuvant treatment for HER2+ IBC applies targeted therapy using the monoclonal HER2-directed antibodies trastuzumab (TTZ) and pertuzumab (Ptz) in combination with conventional chemotherapy drugs, such as taxanes and carboplatin.3 Here, ERBB2 is linked to inflammatory breast carcinoma.